ProtokolPROTOKOL
AncillaryEmergingSERM

Raloxifene (Evista)

SERM

Also known as Evista, Raloxifene

Half-life

~27-32 hours

What is Raloxifene (Evista)?

SERM with strong affinity for breast tissue. Better for established gyno than tamoxifen.

How Raloxifene (Evista) works

SERM antagonizing breast estrogen receptors while agonizing bone to reduce resorption.

Benefits & uses

Common uses: Gynecomastia treatment, PCT, bone density protection, cardiovascular risk reduction.

Raloxifene (Evista) dosage

Protokol doesn't recommend doses for prescription or controlled compounds. Any figures below are reference or observational reports — dosing should be set with a qualified clinician.

Reference range
Literature reports ~60 mg dailyClinical or reference range, not a personal recommendation.

Raloxifene (Evista) half-life

~27-32 hours

Raloxifene (Evista) side effects

Hot flashes, blood clot risk, leg cramps.

  • Leg cramps
  • Hot flashes
  • Venous thromboembolism risk
  • Clot risk (as with SERMs)

Warnings & monitoring

  • Prescription medication — requires a doctor. Clot risk; not for those with clotting history.

Monitoring: Clotting risk awareness; medical supervision.

Track Raloxifene (Evista) in Protokol.

Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.

Download on the App StoreGet it on Google Play

More SERM

For research and educational purposes only. This page is not medical advice and is not a recommendation to use any compound. Many compounds listed are not approved for human use, and some are prescription-only or controlled in your jurisdiction. Dosing figures are reference or observational reports. Talk to a qualified healthcare provider before starting, stopping, or changing anything. Protokol is for tracking purposes only.